Novo Nordisk A/S (NOVO-B.CO)
Novo Nordisk A/S engages in the research, development, manufacture, and distribution of pharmaceutical products, primarily focusing on diabetes and obesity care, as well as rare diseases. The company also provides innovative treatment solutions, including smart insulin pens and applications for insulin dose guidance.
Company Info
Highlights
DKK 2.05T
DKK 23.48
19.60
1.21
DKK 303.14B
DKK 255.65B
DKK 73.25B
DKK 380.00 - DKK 1,012.31
DKK 678.07
Share Price Chart
Loading data...
Compare to other instruments
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Performance
Performance Chart
Loading data...
Returns By Period
Novo Nordisk A/S (NOVO-B.CO) returned -24.28% year-to-date (YTD) and -48.41% over the past 12 months. Over the past 10 years, NOVO-B.CO delivered an annualized return of 11.63%, outperforming the S&P 500 benchmark at 10.88%.
NOVO-B.CO
-24.28%
15.20%
-37.71%
-48.41%
9.63%
18.11%
11.63%
^GSPC (Benchmark)
0.68%
7.17%
-1.66%
11.63%
12.51%
14.34%
10.88%
Monthly Returns
The table below presents the monthly returns of NOVO-B.CO, with color gradation from worst to best to easily spot seasonal factors. Returns are adjusted for dividends.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025 | -2.71% | 6.13% | -25.89% | -7.39% | 6.84% | -24.28% | |||||||
| 2024 | 10.99% | 5.80% | 8.29% | 2.42% | 2.74% | 8.44% | -9.31% | 3.26% | -16.13% | -3.01% | -0.76% | -17.58% | -9.59% |
| 2023 | 0.53% | 5.64% | 9.86% | 3.57% | -0.75% | -1.51% | -0.65% | 17.20% | 1.08% | 5.14% | 2.73% | 0.37% | 50.74% |
| 2022 | -10.73% | 3.96% | 10.84% | 8.47% | -5.49% | 2.54% | 8.49% | -6.70% | -3.92% | 7.58% | 7.92% | 6.11% | 29.53% |
| 2021 | -0.29% | 2.95% | -0.50% | 5.42% | 6.24% | 9.16% | 10.39% | 8.81% | -1.00% | 13.34% | 0.06% | 4.30% | 75.62% |
| 2020 | 6.69% | -4.05% | 4.83% | 6.15% | 0.45% | -1.57% | -2.91% | -0.13% | 6.34% | -6.56% | 2.23% | 1.66% | 12.77% |
| 2019 | 2.11% | 5.80% | 9.89% | -6.57% | -3.32% | 6.29% | -3.14% | 9.69% | -0.04% | 3.89% | 4.20% | 1.43% | 32.92% |
| 2018 | -0.33% | -5.04% | -4.48% | -1.92% | 3.65% | -2.13% | 7.48% | -0.11% | -3.92% | -5.79% | 7.41% | -2.65% | -8.60% |
| 2017 | -2.87% | 0.73% | -1.97% | 10.94% | 5.91% | -0.92% | -3.84% | 12.31% | 1.01% | 5.58% | 1.57% | 3.62% | 35.35% |
| 2016 | -5.00% | -6.29% | 1.55% | 2.17% | 2.45% | -3.68% | 5.86% | -16.71% | -11.93% | -11.98% | -1.82% | 7.02% | -34.55% |
| 2015 | 13.52% | 8.19% | 18.09% | 1.80% | 0.16% | -3.88% | 9.27% | -7.33% | -2.98% | 0.59% | 7.97% | 2.80% | 55.91% |
| 2014 | 10.16% | 17.67% | -2.44% | -1.66% | -4.49% | 8.11% | 2.91% | 0.43% | 8.88% | -4.72% | 1.56% | -4.62% | 33.38% |
Risk-Adjusted Performance
Risk-Adjusted Performance Rank
The current rank of NOVO-B.CO is 5, meaning it’s performing worse than 95% of other stocks on our website when it comes to balancing risk and reward. Below is a breakdown of how it compares using common performance measures.
Risk-Adjusted Performance Indicators
The charts below present risk-adjusted performance metrics for Novo Nordisk A/S (NOVO-B.CO) and compare them to a chosen benchmark (^GSPC). These indicators evaluate an investment's returns against its associated risks.
Loading data...
Dividends
Dividend History
Novo Nordisk A/S provided a 2.45% dividend yield over the last twelve months, with an annual payout of DKK 11.40 per share. The company has been increasing its dividends for 7 consecutive years.
| Period | TTM | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend | DKK 11.40 | DKK 9.90 | DKK 7.08 | DKK 5.58 | DKK 4.68 | DKK 4.30 | DKK 4.08 | DKK 3.93 | DKK 3.80 | DKK 4.70 | DKK 2.50 | DKK 2.25 |
Dividend yield | 2.45% | 1.59% | 1.01% | 1.19% | 1.27% | 2.02% | 2.11% | 2.64% | 2.27% | 3.69% | 1.25% | 1.73% |
Monthly Dividends
The table displays the monthly dividend distributions for Novo Nordisk A/S. The dividends shown in the table have been adjusted to account for any splits that may have occurred.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025 | DKK 0.00 | DKK 0.00 | DKK 7.90 | DKK 0.00 | DKK 0.00 | DKK 7.90 | |||||||
| 2024 | DKK 0.00 | DKK 0.00 | DKK 6.40 | DKK 0.00 | DKK 0.00 | DKK 0.00 | DKK 0.00 | DKK 3.50 | DKK 0.00 | DKK 0.00 | DKK 0.00 | DKK 0.00 | DKK 9.90 |
| 2023 | DKK 0.00 | DKK 0.00 | DKK 4.08 | DKK 0.00 | DKK 0.00 | DKK 0.00 | DKK 0.00 | DKK 3.00 | DKK 0.00 | DKK 0.00 | DKK 0.00 | DKK 0.00 | DKK 7.08 |
| 2022 | DKK 0.00 | DKK 0.00 | DKK 3.45 | DKK 0.00 | DKK 0.00 | DKK 0.00 | DKK 0.00 | DKK 2.13 | DKK 0.00 | DKK 0.00 | DKK 0.00 | DKK 0.00 | DKK 5.58 |
| 2021 | DKK 0.00 | DKK 0.00 | DKK 2.93 | DKK 0.00 | DKK 0.00 | DKK 0.00 | DKK 0.00 | DKK 1.75 | DKK 0.00 | DKK 0.00 | DKK 0.00 | DKK 0.00 | DKK 4.68 |
| 2020 | DKK 0.00 | DKK 0.00 | DKK 2.68 | DKK 0.00 | DKK 0.00 | DKK 0.00 | DKK 0.00 | DKK 1.63 | DKK 0.00 | DKK 0.00 | DKK 0.00 | DKK 0.00 | DKK 4.30 |
| 2019 | DKK 0.00 | DKK 0.00 | DKK 2.58 | DKK 0.00 | DKK 0.00 | DKK 0.00 | DKK 0.00 | DKK 1.50 | DKK 0.00 | DKK 0.00 | DKK 0.00 | DKK 0.00 | DKK 4.08 |
| 2018 | DKK 0.00 | DKK 0.00 | DKK 2.43 | DKK 0.00 | DKK 0.00 | DKK 0.00 | DKK 0.00 | DKK 1.50 | DKK 0.00 | DKK 0.00 | DKK 0.00 | DKK 0.00 | DKK 3.93 |
| 2017 | DKK 0.00 | DKK 0.00 | DKK 2.30 | DKK 0.00 | DKK 0.00 | DKK 0.00 | DKK 0.00 | DKK 1.50 | DKK 0.00 | DKK 0.00 | DKK 0.00 | DKK 0.00 | DKK 3.80 |
| 2016 | DKK 0.00 | DKK 0.00 | DKK 3.20 | DKK 0.00 | DKK 0.00 | DKK 0.00 | DKK 0.00 | DKK 1.50 | DKK 0.00 | DKK 0.00 | DKK 0.00 | DKK 0.00 | DKK 4.70 |
| 2015 | DKK 0.00 | DKK 0.00 | DKK 2.50 | DKK 0.00 | DKK 0.00 | DKK 0.00 | DKK 0.00 | DKK 0.00 | DKK 0.00 | DKK 0.00 | DKK 0.00 | DKK 0.00 | DKK 2.50 |
| 2014 | DKK 2.25 | DKK 0.00 | DKK 0.00 | DKK 0.00 | DKK 0.00 | DKK 0.00 | DKK 0.00 | DKK 0.00 | DKK 0.00 | DKK 0.00 | DKK 2.25 |
Dividend Yield & Payout
Dividend Yield
Novo Nordisk A/S has a dividend yield of 2.45%, which is quite average when compared to the overall market.
Payout Ratio
Novo Nordisk A/S has a payout ratio of 48.55%, which is quite average when compared to the overall market. This suggests that Novo Nordisk A/S strikes a balance between reinvesting profits for growth and paying dividends to shareholders.
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.
Loading data...
Worst Drawdowns
The table below displays the maximum drawdowns of the Novo Nordisk A/S. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the Novo Nordisk A/S was 64.64%, occurring on Jan 4, 1988. Recovery took 774 trading sessions.
The current Novo Nordisk A/S drawdown is 53.85%.
Depth | Start | To Bottom | Bottom | To Recover | End | Total |
|---|---|---|---|---|---|---|
| -64.64% | Feb 14, 1985 | 718 | Jan 4, 1988 | 774 | Feb 1, 1991 | 1492 |
| -61.28% | Jun 26, 2024 | 207 | Apr 22, 2025 | — | — | — |
| -57.03% | Jun 21, 2001 | 275 | Jul 26, 2002 | 912 | Mar 10, 2006 | 1187 |
| -45% | Apr 1, 1998 | 243 | Mar 22, 1999 | 282 | May 3, 2000 | 525 |
| -44.78% | Aug 6, 2015 | 329 | Nov 23, 2016 | 733 | Oct 30, 2019 | 1062 |
Volatility
Volatility Chart
The chart below shows the rolling one-month volatility.
Loading data...
Financials
Financial Performance
The chart below illustrates the trends in the financial health of Novo Nordisk A/S over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.
Earnings Per Share
The chart presents the Earnings Per Share (EPS) performance of Novo Nordisk A/S, comparing actual results with analytics estimates. The company has exceeded analyst expectations for EPS in the past quarter, achieving a 5.0% positive surprise.
Valuation
The Valuation section provides an overview of how Novo Nordisk A/S is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.
PE Ratio
The chart displays the Price-to-Earnings (P/E) ratio for NOVO-B.CO, comparing it with other companies in the Biotechnology industry. Currently, NOVO-B.CO has a P/E ratio of 19.6. This P/E ratio is in line with the industry average, suggesting the stock may be fairly valued relative to its earnings.
PEG Ratio
The chart shows the Price/Earnings to Growth (PEG) ratio for NOVO-B.CO compared to other companies in the Biotechnology industry. NOVO-B.CO currently has a PEG ratio of 1.2. This PEG ratio is close to the industry average, suggesting the stock’s valuation is balanced against its growth outlook.
PS Ratio
This chart shows the Price-to-Sales (P/S) ratio for NOVO-B.CO relative to other companies in the Biotechnology industry. Currently, NOVO-B.CO has a P/S ratio of 6.7. This P/S ratio falls within the average range for the industry, suggesting the stock is fairly valued based on its revenue.
PB Ratio
The chart illustrates the Price-to-Book (P/B) ratio for NOVO-B.CO in comparison with other companies in the Biotechnology industry. Currently, NOVO-B.CO has a P/B value of 14.2. This P/B ratio is higher than most companies in the industry. It may suggest the stock is overvalued or that investors expect the company to generate high returns on its assets.
Income Statement
| TTM | |
|---|---|
Revenue | — |
Total Revenue | — |
Cost Of Revenue | — |
Gross Profit | — |
Operating Expenses | — |
Selling, General & Admin Expenses | — |
R&D Expenses | — |
Depreciation And Amortization | — |
Total Operating Expenses | — |
Income | — |
Income Before Tax | — |
Operating Income | — |
EBITDA | — |
EBIT | — |
Earnings From Continuing Operations | — |
Net Income | — |
Income Tax Expense | — |
Other Non-Operating Income (Expenses) | — |
Extraordinary Items | — |
Discontinued Operations | — |
Effect Of Accounting Charges | — |
Non Recurring | — |
Minority Interest | — |
Other Items | — |
Interest Income | — |
Interest Expense | — |
Net Interest Income | — |